Genitourinary Cancer
Oncology Drug Crash Course: Olaparib (Lynparza)
October 24, 2022
Article
Olaparib is an oral drug manufactured in 150-mg and 100-mg tablets. Olaparib is taken by mouth, twice daily. It can be taken without or without food.
Promising Selpercatinib Data Highlight Value of RET Fusion Testing for Patients With Solid Tumors
October 17, 2022
Article
Selpercatinib demonstrated a promising efficacy profile in patients with RET-fusion positive solid tumors.
Advanced Practice Providers Are Uniquely Suited for Survivorship Care
October 13, 2022
Article
Advanced practice providers are the future of survivorship care because of the tremendous value they offer to the practice and its patients.
Tivozanib Outperforms Sorafenib in Extending Overall Survival in Advanced RCC
October 12, 2022
Article
Tivozanib, an oral VEGF inhibitor, improved overall survival in patients with relapsed or refractory, advanced renal cell carcinoma.
Supporting the Novice Oncology NP: The Benefits of Preceptorship
October 10, 2022
Article
Structured preceptorships promote competence, confidence, and job satisfaction in new oncology nurse practitioners.
Rucaparib Boosts Radiographic Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer
October 07, 2022
Article
The median radiographic progression-free survival (rPFS) was 11.2 months among patients with castration-resistant prostate cancer who received rucaparib. In the control arm, median rPFS was 6.4 months.
Clinical Trials Continue to Propel Field of Oncology with Nurses on The Frontline
October 07, 2022
Article
Anne Delengowski, RN, MSN, AOCN, CCCTM, discusses the evolving role of the oncology nurse in clinical trial research.
Oncology Nursing News Top Stories: September 2022
September 29, 2022
Article
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from September 2022.
Rise of Oral Cancer Drugs Signal Deeper Financial Toxicity Issues for Patients
September 28, 2022
Article
Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.
ASCO Guidelines Aim to Outline Updated Recommendations for ccRCC Management
September 27, 2022
Article
ASCO has released new guidelines concerning the optimal treatment of patients with metastatic clear cell renal cell carcinoma following a systematic literature review by an expert panel.